12
Participants
Start Date
April 11, 2019
Primary Completion Date
June 30, 2021
Study Completion Date
September 30, 2023
Palbociclib
Given PO (or via NG- tube)
Cytarabine
Given intrathecally (IT)
Methotrexate
Given intrathecally (IT)
Hydrocortisone
Given IT
Doxorubicin
Given intravenously (IV)
Prednisolone
Either prednisone or prednisolone is given PO
Vincristine
Given IV
Pegaspargase
Given IV
Hydrocortisone
Given intrathecally (IT)
Prednisone
Either prednisone or prednisolone is given PO
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Children's Healthcare of Atlanta - Egleston, Atlanta
Children's Hospital of Alabama, Birmingham
Saint Jude Children's Research Hospital, Memphis
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children, Indianapolis
C S Mott Children's Hospital, Ann Arbor
University of Minnesota/Masonic Cancer Center, Minneapolis
University of Oklahoma Health Sciences Center, Oklahoma City
Children's Hospital Colorado, Aurora
Primary Children's Hospital, Salt Lake City
Loma Linda University Medical Center, Loma Linda
Children's Hospital of Orange County, Orange
Lucile Packard Children's Hospital Stanford University, Palo Alto
Seattle Children's Hospital, Seattle
Children's Oncology Group
NETWORK